Developer docs
API playgroundTry for free, no card

Search company profiles

Brandon Capital

Full company profile

uuid00003e4

Namestring
Brandon Capital
Legal namestring
Brandon Capital Partners
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Brandon Capital Partners is a Melbourne-headquartered life sciences venture capital firm that manages six successive funds totaling over A$700 million in assets under management. The firm invests across the full life sciences spectrum, from seed-stage ventures through to expansion capital, with a focus on biotechnology, pharmaceuticals, and medical devices. Its portfolio includes companies developing antibody-drug conjugates (Pheon Therapeutics, Myricx Bio), radiopharmaceuticals (AdvanCell), immunotherapies (CatalYm, Pathios Therapeutics), neurodegenerative therapies (NRG Therapeutics, AstronauTx), and respiratory therapeutics (ENA Respiratory), among others. Notable exits include Spinifex Pharmaceuticals (acquired by Novartis for $700M) and Elastagen (acquired by Allergan for up to $120M).

The firm's go-to-market centers on a co-investment model with a concentrated base of Australian institutional Limited Partners, led by superannuation funds HESTA, HostPlus, and StatewideSuper, alongside biotech company CSL and government vehicles including the National Reconstruction Fund Corporation and the Western Australian Government. The firm was originally established through the Medical Research Commercialisation Fund (MRCF) in 2007 and rebranded its incubation platform to Brandon BioCatalyst in March 2022. Brandon BioCatalyst coordinates over 50 Australian and New Zealand research organizations and operates the CUREator national biotech incubator, providing an internal deal-sourcing engine alongside the firm's external investment activity.

Brandon Capital generates revenue through standard VC mechanisms: recurring management fees on committed and invested capital (typically 1.5-2.5% of AUM during the investment period) and performance-based carried interest (typically 20%) on profitable exits above the hurdle rate. Revenue is not publicly disclosed. The firm operates from offices in Melbourne, Sydney, San Francisco, and London, and its Fund VI closed at A$439 million in July 2025, the largest fundraise in its history. Chris Nave serves as Partner, Managing Director, and Co-Founder.

Short descriptiontext

Brandon Capital Partners is a Melbourne-based life sciences venture capital firm managing six successive funds totaling over A$700M, investing from seed to expansion stage across Australia, New Zealand, the US, and the UK for institutional LPs and biotech entrepreneurs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech venture investing, medical research funding, pharmaceutical venture capital, healthcare startup investment
Industry3 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Life Sciences Investment Management
Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

VC fund management fees charged on assets under management

brandoncapital.vc
2Carried Interest
TypeLicensing Royalties
Description

Performance-based carried interest from successful portfolio company exits, typically 20% of profits above the hurdle rate

brandoncapital.vc
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Brandon Capital Partners is Australasia's leading life sciences venture capital firm that invests in early-stage through expansion-stage biotechnology, medical device, and pharmaceutical companies. The firm manages multiple successive life sciences venture funds (most recently Fund VI at A$439 million) and supports portfolio companies from proof-of-concept through commercialisation via direct equity investment, operational support, and access to its network of over 50 Australian and New Zealand research institutions through the Brandon BioCatalyst program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Spinifex Pharmaceuticals acquired by Novartis for $700 million
+2 more records
Product overview1 text field

Brandon Capital Partners is a life sciences venture capital firm that invests in and supports early-stage through expansion-stage life science companies. Rather than offering a product platform, Brandon Capital operates as a capital allocator and investment manager, deploying funds into biotechnology, medical device, and pharmaceutical companies across Australia, New Zealand, the United States, and the United Kingdom. The firm manages multiple investment funds and provides operational support to portfolio companies through its Brandon BioCatalyst initiative, which includes the CUREator national biotech incubator. The firm does not offer a unified software product or technology platform; its offerings consist of venture capital funding, mentorship, and access to a network of research institutions and investors for life sciences entrepreneurs.

Product and service3 records
1Brandon Capital Fund VI (BB6)
CategoryVenture capital fund
Description

Brandon Capital's sixth life sciences venture capital fund providing investment capital from early-stage seed through to expansion stage for Australian and New Zealand life sciences companies. The fund raised A$439 million at final close in July 2025 and is backed by institutional Limited Partners including HESTA, HostPlus, CSL, QIC, NRFC, and the Western Australian Government.

2Brandon BioCatalyst (formerly MRCF)
CategoryBiotech incubator and collaboration program
Description

Brandon Capital-managed national life sciences investment collaboration of over 50 organisations including research institutes across Australia and New Zealand. The program supports biotech startups and researchers with funding and commercialisation support, and includes the Biomedical Translation Fund (BTF) programs.

3CUREator National Biotech Incubator
CategoryBiotech incubator
Description

National biotech incubator under the Brandon BioCatalyst initiative that supports and accelerates the development of Australian biotech innovations through funding and incubation programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1CatalYm
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-24
Description

German biotech company with multiple visugromab trials in NSCLC, HCC, and cachexia; Brandon Capital is an investor and active supporter of clinical development program expansion

brandoncapital.vc
Strategic tierCoreTypeOthers
Description

Brandon Capital-managed Medical Research Commercialisation Fund collaboration of over 50 organisations including research institutes across Australia and New Zealand; also includes Biomedical Translation Fund (BTF) programs

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1GBS Ventures
TypeRegional player
Description

Australian life sciences venture capital firm. Regional peer with comparable Australian biotech investment mandate and similar early-to-growth stage focus.

TypeDirect peer
Description

Australian venture capital firm with healthcare and biotech specialist funds. Direct peer given its overlapping Australasian life sciences investment mandate and comparable fund sizes.

TypeBroad incumbent
Description

European life sciences VC firm. Comparable given its co-lead role in Myricx Pharma's £4.5M seed alongside Brandon Capital and overlapping ADC/oncology investment focus.

TypeDirect peer
Description

UK/Australian deep-tech and life sciences VC firm that commercialises university research. Direct peer given its co-investment with Brandon (e.g., Ankere Therapeutics seed round) and similar academic-commercialisation model.

5Uniseed
TypeDirect peer
Description

Australian university-focused venture fund investing in life sciences and deep tech from Australian research institutions. Direct peer with overlapping academic commercialisation deal flow.

TypeBroad incumbent
Description

Novo Nordisk Foundation's venture arm focused on life sciences. Comparable given its co-lead role in Myricx Bio's $114M Series A alongside Brandon Capital and similar therapeutic focus.

TypeRegional player
Description

Australian-based life sciences investment manager. Regional peer operating in the same Australasian life sciences ecosystem with overlapping biotech and medtech portfolio exposure.

TypeBroad incumbent
Description

European life sciences venture capital firm with a focused biotech mandate. Comparable as a specialist late-stage life sciences investor operating across similar therapeutic areas to Brandon Capital's portfolio.

TypeBroad incumbent
Description

Global life sciences-focused VC firm. Comparable as a specialist life sciences investor and active co-investor with Brandon Capital in deals like AdvanCell's $112M Series C and NRG Therapeutics' £50M Series B.

TypeBroad incumbent
Description

Global life sciences investment firm. Comparable given its co-lead role in AdvanCell's Series C and shared life sciences venture focus with Brandon Capital.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment79 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brandon Capital

Venture Capital / Life Sciences Investment Managementbrandoncapital.vc

Brandon Capital Partners is a Melbourne-based life sciences venture capital firm managing six successive funds totaling over A$700M, investing from seed to expansion stage across Australia, New Zealand, the US, and the UK for institutional LPs and biotech entrepreneurs.

What Brandon Capital does

Brandon Capital Partners is a Melbourne-headquartered life sciences venture capital firm that manages six successive funds totaling over A$700 million in assets under management. The firm invests across the full life sciences spectrum, from seed-stage ventures through to expansion capital, with a focus on biotechnology, pharmaceuticals, and medical devices. Its portfolio includes companies developing antibody-drug conjugates (Pheon Therapeutics, Myricx Bio), radiopharmaceuticals (AdvanCell), immunotherapies (CatalYm, Pathios Therapeutics), neurodegenerative therapies (NRG Therapeutics, AstronauTx), and respiratory therapeutics (ENA Respiratory), among others. Notable exits include Spinifex Pharmaceuticals (acquired by Novartis for $700M) and Elastagen (acquired by Allergan for up to $120M).

The firm's go-to-market centers on a co-investment model with a concentrated base of Australian institutional Limited Partners, led by superannuation funds HESTA, HostPlus, and StatewideSuper, alongside biotech company CSL and government vehicles including the National Reconstruction Fund Corporation and the Western Australian Government. The firm was originally established through the Medical Research Commercialisation Fund (MRCF) in 2007 and rebranded its incubation platform to Brandon BioCatalyst in March 2022. Brandon BioCatalyst coordinates over 50 Australian and New Zealand research organizations and operates the CUREator national biotech incubator, providing an internal deal-sourcing engine alongside the firm's external investment activity.

Brandon Capital generates revenue through standard VC mechanisms: recurring management fees on committed and invested capital (typically 1.5-2.5% of AUM during the investment period) and performance-based carried interest (typically 20%) on profitable exits above the hurdle rate. Revenue is not publicly disclosed. The firm operates from offices in Melbourne, Sydney, San Francisco, and London, and its Fund VI closed at A$439 million in July 2025, the largest fundraise in its history. Chris Nave serves as Partner, Managing Director, and Co-Founder.

Brandon Capital firmographics

Firmographics
Name
Brandon Capital
Legal name
Brandon Capital Partners
Website
https://brandoncapital.vc
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Brandon Capital Partners is a Melbourne-based life sciences venture capital firm managing six successive funds totaling over A$700M, investing from seed to expansion stage across Australia, New Zealand, the US, and the UK for institutional LPs and biotech entrepreneurs.
Ownership category
akta.pro rank

Brandon Capital industry classification

Industry
Product category
Venture Capital / Life Sciences Investment Management
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)

Keywords

  • Life sciences venture capital
  • Biotech venture investing
  • Medical research funding
  • Pharmaceutical venture capital
  • Healthcare startup investment

Where Brandon Capital is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices4 records

Markets served

Brandon Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Management Fees: VC fund management fees charged on assets under management
  2. Carried Interest: Performance-based carried interest from successful portfolio company exits, typically 20% of profits above the hurdle rate

Distribution channels1 record

Marketing channels4 records

Brandon Capital product offering

Product offering

Core offering

Brandon Capital Partners is Australasia's leading life sciences venture capital firm that invests in early-stage through expansion-stage biotechnology, medical device, and pharmaceutical companies. The firm manages multiple successive life sciences venture funds (most recently Fund VI at A$439 million) and supports portfolio companies from proof-of-concept through commercialisation via direct equity investment, operational support, and access to its network of over 50 Australian and New Zealand research institutions through the Brandon BioCatalyst program.

Product overview

Brandon Capital Partners is a life sciences venture capital firm that invests in and supports early-stage through expansion-stage life science companies. Rather than offering a product platform, Brandon Capital operates as a capital allocator and investment manager, deploying funds into biotechnology, medical device, and pharmaceutical companies across Australia, New Zealand, the United States, and the United Kingdom. The firm manages multiple investment funds and provides operational support to portfolio companies through its Brandon BioCatalyst initiative, which includes the CUREator national biotech incubator. The firm does not offer a unified software product or technology platform; its offerings consist of venture capital funding, mentorship, and access to a network of research institutions and investors for life sciences entrepreneurs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Brandon Capital Fund VI (BB6) Brandon Capital's sixth life sciences venture capital fund providing investment capital from early-stage seed through to expansion stage for Australian and New Zealand life sciences companies. The fund raised A$439 million at final close in July 2025 and is backed by institutional Limited Partners including HESTA, HostPlus, CSL, QIC, NRFC, and the Western Australian Government.
  • Brandon BioCatalyst (formerly MRCF) Brandon Capital-managed national life sciences investment collaboration of over 50 organisations including research institutes across Australia and New Zealand. The program supports biotech startups and researchers with funding and commercialisation support, and includes the Biomedical Translation Fund (BTF) programs.
  • CUREator National Biotech Incubator National biotech incubator under the Brandon BioCatalyst initiative that supports and accelerates the development of Australian biotech innovations through funding and incubation programs.

Quantifiable outcome

  • Spinifex Pharmaceuticals acquired by Novartis for $700 million
  • +2 more outcomes

Companies that use Brandon Capital

Customer profile

Segments3 records

Ideal customer profiles2 records

Brandon Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Brandon Capital partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CatalYmcoreStrategic or Co-development Partner · 24 April 2026German biotech company with multiple visugromab trials in NSCLC, HCC, and cachexia; Brandon Capital is an investor and active supporter of clinical development program expansion
  • Brandon BioCatalyst (formerly MRCF)coreOthersBrandon Capital-managed Medical Research Commercialisation Fund collaboration of over 50 organisations including research institutes across Australia and New Zealand; also includes Biomedical Translation Fund (BTF) programs

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Brandon Capital competitors and assessment

Company assessment

Regional players

  • GBS Ventures: Australian life sciences venture capital firm. Regional peer with comparable Australian biotech investment mandate and similar early-to-growth stage focus.
  • BioScience Managers: Australian-based life sciences investment manager. Regional peer operating in the same Australasian life sciences ecosystem with overlapping biotech and medtech portfolio exposure.

Direct peers

  • OneVentures: Australian venture capital firm with healthcare and biotech specialist funds. Direct peer given its overlapping Australasian life sciences investment mandate and comparable fund sizes.
  • IP Group: UK/Australian deep-tech and life sciences VC firm that commercialises university research. Direct peer given its co-investment with Brandon (e.g., Ankere Therapeutics seed round) and similar academic-commercialisation model.
  • Uniseed: Australian university-focused venture fund investing in life sciences and deep tech from Australian research institutions. Direct peer with overlapping academic commercialisation deal flow.

Broad incumbents

  • Sofinnova Partners: European life sciences VC firm. Comparable given its co-lead role in Myricx Pharma's £4.5M seed alongside Brandon Capital and overlapping ADC/oncology investment focus.
  • Novo Holdings (Novo Seeds): Novo Nordisk Foundation's venture arm focused on life sciences. Comparable given its co-lead role in Myricx Bio's $114M Series A alongside Brandon Capital and similar therapeutic focus.
  • Forbion: European life sciences venture capital firm with a focused biotech mandate. Comparable as a specialist late-stage life sciences investor operating across similar therapeutic areas to Brandon Capital's portfolio.
  • SV Health Investors: Global life sciences-focused VC firm. Comparable as a specialist life sciences investor and active co-investor with Brandon Capital in deals like AdvanCell's $112M Series C and NRG Therapeutics' £50M Series B.
  • Abingworth: Global life sciences investment firm. Comparable given its co-lead role in AdvanCell's Series C and shared life sciences venture focus with Brandon Capital.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Brandon Capital social profiles

Digital presence

Brandon Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brandon Capital leadership team

Management profile

Number of profiles

Profiles1 record

Brandon Capital subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Brandon Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brandon Capital M&A and investment

M&A and investment

M&A

Investments79 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brandon Capital

What does Brandon Capital do?

Brandon Capital Partners is Australasia's leading life sciences venture capital firm that invests in early-stage through expansion-stage biotechnology, medical device, and pharmaceutical companies. The firm manages multiple successive life sciences venture funds (most recently Fund VI at A$439 million) and supports portfolio companies from proof-of-concept through commercialisation via direct equity investment, operational support, and access to its network of over 50 Australian and New Zealand research institutions through the Brandon BioCatalyst program.

Is Brandon Capital a public or private company?

Brandon Capital is a private company. It is classified as management employee owned and is currently operating.

When was Brandon Capital founded?

Brandon Capital was founded in 2006. It employs 11 to 50 people.

Where is Brandon Capital based?

Brandon Capital is headquartered in Melbourne, Australia, in the Oceania region.

How does Brandon Capital make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are Brandon Capital's main competitors?

Regional players on record are GBS Ventures and BioScience Managers. Direct peers are OneVentures, IP Group and Uniseed. Broad incumbents are Sofinnova Partners, Novo Holdings (Novo Seeds), Forbion, SV Health Investors and Abingworth.

Does Brandon Capital have an API?

No public API is recorded for Brandon Capital.

What industry is Brandon Capital in?

Brandon Capital's product category is Venture Capital / Life Sciences Investment Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing InfrastructureAdvanCell closed a $315 million Series D financing led by Ally Bridge Group and co-led by Alpha Wave, with participation from new investors including Bain Capital Life Sciences and Fidelity. Proceeds will advance ADVC001, a Lead-212 PSMA-targeted therapy for metastatic prostate cancer, toward Phase 3 development and expand its vertically integrated manufacturing infrastructure.The Pharma LetterAdvanCell raises $315 million to accelerate lead-212 radiopharma pipelineAdvanCell closed an oversubscribed $315 million Series D financing to advance its lead-212 radiopharma pipeline and expand manufacturing. The round was led by Ally Bridge Group and co-led by Alpha Wave, with participation from Bain Capital Life Sciences, Fidelity, T Rowe Price, and others.FinSMEsAdvanCell Closes US $315M in Series D FundingAdvanCell raised $315M in Series D funding led by Ally Bridge Group and Alpha Wave, with participation from Bain Capital Life Sciences, Fidelity, and others. The company will use the funds to advance its Lead-212 PSMA-targeted therapy ADVC001 toward Phase 3 and expand its manufacturing infrastructure.GlobeNewswireBrandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer TherapeuticsNovartis has agreed to acquire UK-based pre-clinical oncology company Myricx Bio for up to US$1.5 billion (~A$2.16bn), including an upfront cash payment of US$1.1 billion plus potential milestone payments. The acquisition, expected to close in H2 2026 subject to regulatory approvals, will give Novartis access to Myricx Bio's novel N-myristoyltransferase inhibitor (NMTi) payload platform for antibody-drug conjugates (ADCs) and two lead ADC assets targeting solid tumours. Brandon Capital, which co-founded and seeded Myricx Bio in 2019 and maintained a substantial shareholding through the Series A and acquisition, will generate significant returns for its investors including Australian superannuation funds Hostplus, HESTA, and Aware Super.BioSpaceSofinnova Partners Announces Myricx Bio Agrees to Be Acquired by NovartisNovartis agreed to acquire Myricx Bio for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestones. The deal combines Novartis' oncology expertise with Myricx's NMTi payload platform for antibody-drug conjugates. The transaction is expected to close in H2 2026.MorningstarSofinnova Partners Announces Myricx Bio Agrees to Be Acquired by NovartisMyricx Bio agreed to be acquired by Novartis for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestone payments. The deal combines Novartis' oncology expertise with Myricx's NMTi payload platform targeting solid tumors. The transaction is expected to close in H2 2026.Medical BuyerBrandon Capital opens second funding round for CDCD programBrandon Capital has opened the second funding round for the CUREator+ Dementia and Cognitive Decline incubator program, offering up to $5 million in non-dilutive grant funding per project to Australian SMEs and researchers. The program is a partnership between Brandon BioCatalyst, ANDHealth, and Dementia Australia, funded by the Federal Government's Medical Research Future Fund, and supports the commercial development of therapeutics, diagnostics, medical devices, and digital health technologies for dementia care. Successful applicants will receive access to commercial guidance, international expert networks, and mentorship alongside funding to advance their projects toward commercialization.BioSpaceAstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical OfficerAstronauTx appointed Dr. Michelle Mellion as Chief Medical Officer and Deb Gouveia as Vice President of Clinical Operations and Development Strategy. The appointments aim to strengthen clinical development capabilities as the company prepares to advance its sleep-architecture therapies into clinical trials for Alzheimer's disease.Business Wire BlogAustralian Breast Cancer Innovators Close $27M Private Funding RoundOncoRes Medical announced the closing of an AUD $27 million private funding round to advance its Elora™ Quantitative Micro-Elastography Imaging System, which provides real-time intraoperative tumor assessment during breast-conserving surgery. The funding round attracted cornerstone investment from Brandon Capital Partners along with Morgans, Radar Ventures, family offices, and The Table Club, with proceeds earmarked for an Australian clinical trial across six hospitals, product development, U.S. regulatory milestones, and manufacturing for a U.S. Pivotal Trial. The company also appointed healthcare veteran Renee Ryan to its Board and announced plans to explore the technology's application in other cancer types, including prostate cancer.